Home LiteratureArticle Details
PMID: 8336729 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

Oncogenic activation of c-ABL by mutation within its last exon.

Molecular and cellular biology ·Vol. 13 ·No. 8 ·1993-08-00 ·Pages 4967-75

Goga A, McLaughlin J, Pendergast AM, Parmar K, Muller A, Rosenberg N, Witte ON

Abstract

The c-ABL proto-oncogene is a predominantly nuclear localized tyrosine kinase. A random mutagenesis scheme was used to isolate c-ABL mutants whose expression produced a transformed phenotype in rodent fibroblast cells. An in-frame deletion within the central region of the last exon was identified in one ABL mutant. The mechanism of c-ABL oncogenic activation by mutation within the last exon differs both functionally and structurally from those of v-ABL and BCR/ABL. This class of ABL mutants shows increased tyrosine phosphorylation of cellular proteins in vivo but low levels of autophosphorylation. Last-exon ABL mutants are distinguished from v-ABL or BCR/ABL by their inability to transform primary bone marrow cells or support the growth of transformed pre-B cells. These findings define a new mechanism of oncogenic activation for the ABL kinase through mutations in the last exon which do not require amino-terminal deletions or mutations within the src homology regions.

Related Genes
ABL
MeSH Terms
3T3 Cells Animals Base Sequence Cell Compartmentation Cell Transformation, Neoplastic/genetics Cytoplasm/metabolism DNA Mutational Analysis DNA-Binding Proteins/genetics,metabolism Exons Genes, abl Mice Molecular Sequence Data Mutation Oligonucleotides/chemistry Protein Kinases/metabolism Proto-Oncogene Proteins c-abl/genetics Recombinant Proteins Sequence Deletion Structure-Activity Relationship
Chemicals
DNA-Binding Proteins Oligonucleotides Recombinant Proteins Protein Kinases Proto-Oncogene Proteins c-abl
Authors & Affiliations
7 authors, click to expand affiliations / ORCID
Goga A
Department of Microbiology and Molecular Genetics, University of California, Los Angeles 90024.
McLaughlin J
Pendergast A M
Parmar K
Muller A
Rosenberg N
Witte O N
References (33)
33 references, click to expand
  1. BCR first exon sequences specifically activate the BCR/ABL tyrosine kinase oncogene of Philadelphia chromosome-positive human leukemias.
    Mol Cell Biol. 1991 Apr;11(4):1785-92 PMID: 2005881
  2. Activation of tyrosinase kinase and microfilament-binding functions of c-abl by bcr sequences in bcr/abl fusion proteins.
    Mol Cell Biol. 1991 Mar;11(3):1553-65 PMID: 1705008
  3. Evidence for regulation of the human ABL tyrosine kinase by a cellular inhibitor.
    Proc Natl Acad Sci U S A. 1991 Jul 1;88(13):5927-31 PMID: 1712111
  4. Cell cycle-regulated binding of c-Abl tyrosine kinase to DNA.
    Science. 1992 Apr 17;256(5055):382-5 PMID: 1566087
  5. c-abl has a sequence-specific enhancer binding activity.
    Cell. 1992 May 29;69(5):751-7 PMID: 1591775
  6. Lymphoid cells transformed by Abelson virus require the v-abl protein-tyrosine kinase only during early G1.
    Proc Natl Acad Sci U S A. 1992 Aug 1;89(15):6683-7 PMID: 1379715
  7. Identification of a protein that binds to the SH3 region of Abl and is similar to Bcr and GAP-rho.
    Science. 1992 Aug 7;257(5071):803-6 PMID: 1379745
  8. SH2 and SH3 domains: from structure to function.
    Cell. 1992 Oct 30;71(3):359-62 PMID: 1423600
  9. SH1 domain autophosphorylation of P210 BCR/ABL is required for transformation but not growth factor independence.
    Mol Cell Biol. 1993 Mar;13(3):1728-36 PMID: 8441409
  10. En bloc substitution of the Src homology region 2 domain activates the transforming potential of the c-Abl protein tyrosine kinase.
    Proc Natl Acad Sci U S A. 1993 Apr 15;90(8):3457-61 PMID: 7682703
  11. High efficiency polyoma DNA transfection of chloroquine treated cells.
    Nucleic Acids Res. 1983 Mar 11;11(5):1295-308 PMID: 6298741
  12. Cellular RNA homologous to the Abelson murine leukemia virus transforming gene: expression and relationship to the viral sequence.
    Mol Cell Biol. 1983 May;3(5):773-9 PMID: 6306446
  13. Only site-directed antibodies reactive with the highly conserved src-homologous region of the v-abl protein neutralize kinase activity.
    J Virol. 1984 Jul;51(1):223-32 PMID: 6610061
  14. An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity.
    Cell. 1984 Jul;37(3):1035-42 PMID: 6204766
  15. Alternative 5' exons in c-abl mRNA.
    Cell. 1986 Feb 28;44(4):577-86 PMID: 3512096
  16. Monoclonal antibodies specific for v-abl- and c-abl-encoded molecules.
    J Virol. 1986 Mar;57(3):1182-6 PMID: 3005619
  17. In vitro transformation of immature hematopoietic cells by the P210 BCR/ABL oncogene product of the Philadelphia chromosome.
    Proc Natl Acad Sci U S A. 1987 Sep;84(18):6558-62 PMID: 3498165
  18. The viral and cellular forms of the Abelson (abl) oncogene.
    Adv Virus Res. 1988;35:39-81 PMID: 2852893
  19. Deletion of an N-terminal regulatory domain of the c-abl tyrosine kinase activates its oncogenic potential.
    EMBO J. 1989 Jan;8(1):137-47 PMID: 2496972
  20. N-terminal mutations activate the leukemogenic potential of the myristoylated form of c-abl.
    EMBO J. 1989 Feb;8(2):449-56 PMID: 2542016
  21. Deletions within the amino-terminal half of the c-src gene product that alter the functional activity of the protein.
    Mol Cell Biol. 1989 Mar;9(3):1109-19 PMID: 2471059
  22. The BCR-ABL oncogene transforms Rat-1 cells and cooperates with v-myc.
    Mol Cell Biol. 1989 Mar;9(3):1263-70 PMID: 2725497
  23. The mouse type IV c-abl gene product is a nuclear protein, and activation of transforming ability is associated with cytoplasmic localization.
    Cell. 1989 Aug 25;58(4):669-78 PMID: 2670246
  24. Similarity in membrane proteins.
    Nature. 1989 Dec 7;342(6250):624 PMID: 2594066
  25. Phosphorylation of GAP and GAP-associated proteins by transforming and mitogenic tyrosine kinases.
    Nature. 1990 Jan 25;343(6256):377-81 PMID: 1689011
  26. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products.
    Science. 1990 Mar 2;247(4946):1079-82 PMID: 2408149
  27. Site-directed mutagenesis of the SH2- and SH3-coding domains of c-src produces varied phenotypes, including oncogenic activation of p60c-src.
    Mol Cell Biol. 1990 Apr;10(4):1307-18 PMID: 2108315
  28. bcr/abl and src but not myc and ras replace v-abl in lymphoid transformation.
    Mol Cell Biol. 1990 Aug;10(8):4365-9 PMID: 2164639
  29. The complete coding sequence of arg defines the Abelson subfamily of cytoplasmic tyrosine kinases.
    Proc Natl Acad Sci U S A. 1990 Aug;87(15):5802-6 PMID: 2198571
  30. Oncogenes and signal transduction.
    Cell. 1991 Jan 25;64(2):281-302 PMID: 1846320
  31. Activation of phosphatidylinositol 3-kinase in cells expressing abl oncogene variants.
    Mol Cell Biol. 1991 Feb;11(2):1107-13 PMID: 1846663
  32. Hyperexpression of interleukin-7 is not necessary or sufficient for transformation of a pre-B lymphoid cell line.
    Mol Cell Biol. 1991 Feb;11(2):854-63 PMID: 1990288
  33. SH2 and SH3 domains: elements that control interactions of cytoplasmic signaling proteins.
    Science. 1991 May 3;252(5006):668-74 PMID: 1708916
Article Info
Journal
Molecular and cellular biology
Abbr.
Mol Cell Biol
ISSN
0270-7306
Published
1993-08-00
Pages
4967-75
Language
English
Region
United States
NLM ID
8109087
PMCID
PMC360140
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com